Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) Price Target at $23.43

Cellebrite DI Ltd. (NASDAQ:CLBT) has earned an average recommendation of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $23.43.

Several brokerages have recently issued reports on CLBT. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a report on Friday, February 14th. Craig Hallum boosted their target price on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Finally, Lake Street Capital increased their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th.

Institutional Investors Weigh In On Cellebrite DI

A number of hedge funds and other institutional investors have recently bought and sold shares of CLBT. Pathway Financial Advisers LLC boosted its position in Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock worth $74,000 after acquiring an additional 4,118 shares during the last quarter. Meitav Investment House Ltd. boosted its holdings in Cellebrite DI by 29.7% during the third quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock worth $34,797,000 after purchasing an additional 473,293 shares during the last quarter. Pembroke Management LTD grew its position in Cellebrite DI by 24.3% in the third quarter. Pembroke Management LTD now owns 1,908,345 shares of the company’s stock valued at $32,137,000 after purchasing an additional 372,619 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in Cellebrite DI by 8.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 51,155 shares of the company’s stock valued at $861,000 after buying an additional 3,912 shares during the last quarter. Finally, Harbor Capital Advisors Inc. lifted its position in Cellebrite DI by 96.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 95,351 shares of the company’s stock worth $1,606,000 after buying an additional 46,727 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Trading Up 0.3 %

NASDAQ CLBT opened at $18.56 on Wednesday. Cellebrite DI has a 12 month low of $10.24 and a 12 month high of $26.30. The company has a market capitalization of $3.82 billion, a PE ratio of -13.35, a P/E/G ratio of 4.27 and a beta of 1.47. The stock has a 50-day simple moving average of $22.31 and a 200 day simple moving average of $19.65.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, sell-side analysts predict that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.